We deliver finished formulation and APIs from award winning facilities while improving our R&D and discovery pipeline
Cardiology and Diabetology | Natco Pharma
NATCO has launched Cardiology and Diabetology (CnD) division (in early 2017), keeping in mind our mission of making specialty medicines accessible to all.
Our current portfolio of products include:
The cardiovascular range which offers a comprehensive list of anti-hypertensives including major brands like Cilnidipine & its combinations (NATCOCIL & range) which is a first line treatment of hypertension, Ivabradine (IVABRATCO) for stable angina & CHF.
The cardiovascular range offers the complete basket of Novel oral anti-coagulant (NOAC) brands of DABIGAT® (Dabigatran), APIGAT®(Apixaban) and Rpigat® (Rivaroxaban). We also have anti-platelet agents like TICAGAT® (Ticagrelor).
The anti-diabetics range which offers one of the highest prescribed DPP4 inhibitors – Vildagliptin, Vildagliptin+Metformin, Teneligliptin & Teneligliptin+Metformin for the treatment of type 2 diabetes Mellitus to cater to the Diabetes capital of the world.
We are aggressively working on a pipeline of products which will uniquely differentiate us from most other players in the segment.
Products are available against the prescription of Registered Medical Practitioners through our authorized distributors in the domestic market. Enquiries can be sent through the link provided with the respective products.